CANbridge Forms Rare Disease Drug Partnership with WuXi Biologics

CANbridge Pharma of Beijing and WuXi Biologics announced a strategic partnership to develop new treatments for rare diseases. The partnership combines WuXi Biologics’ discovery, development and manufacturing capabilities with CANbridge’s expertise in clinical development of orphan drugs. CANbridge expects to file the first China rare disease IND application from the partnership in 2019. WuXi Biologics will receive upfront payments, plus potential milestones and royalties on global sales for the partnership's programs. More details....

Stock Symbols: (HK: 2269)

Share this with colleagues:

Original Article: CANbridge Forms Rare Disease Drug Partnership with WuXi Biologics

More From BioPortfolio on "CANbridge Forms Rare Disease Drug Partnership with WuXi Biologics"